Genetic Basis For Variation In NSAID Analgesia In A Clinical Model Of Acute Pain
NCT00115752 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96
Last updated 2017-07-02
Summary
This study will evaluate how genetic makeup contributes to the variation in people regarding their sensitivity to and experience of pain. Scientists believe that differences in information found in genes may explain why an analgesic drug, that is, one that treats pain, works effectively for some people but not for others. The study will explore pain that is acute (fast and short period). Knowledge gained from this ongoing study may permit development of an individualized analgesic drug prescription.
Patients ages 16 to 35 who are in good health and have been referred for removal of impacted wisdom teeth; who are not allergic to aspirin or other nonsteroidal anti-inflammatory drugs (known as NSAIDs), sulfites, or certain anesthetics; who are not pregnant or nursing; and who are willing to have a biopsy before and after dental surgery are eligible for this study.
Patients will come to the clinic for one test visit and one treatment visit. During the first visit, a questionnaire will evaluate patients' psychological state, including mood and depression. There will be a clinical examination of their wisdom teeth. A blood sample of 10 milliliters (about 0.4 ounces) will be collected from the forearm to provide DNA material containing genes stored in cells. The primary genetic analysis will be done at NIH, although the DNA collected might also be sent to a laboratory outside NIH. DNA samples will be coded so that names of patients cannot be traced.
During the second visit, two of the patients' lower wisdom teeth will be removed. Patients will be given a local anesthetic in the mouth and a sedative given through a vein in the arm. While the mouth is numb, a small piece of tissue will be removed from inside the cheek, near the wisdom tooth. It is the first biopsy. After the two wisdom teeth are removed, a small piece of tubing will be placed into both sides of the mouth where the teeth were removed. Every 20 minutes, for the next 3 hours, the researchers will collect inflammatory fluid from the tubing, to measure the chemicals thought to cause pain and swelling. Also every 20 minutes, patients will rate the pain they feel by answering questions. If there is pain before 3 hours following surgery, they will receive a dose of fentanyl to relieve moderate to severe pain. A second biopsy will occur 3 hours after surgery, to measure changes in chemicals produced in response to surgery. Immediately afterward, patients will receive 30 mg of ketorolac (Toradol) whether or not pain is felt. They will answer questionnaires about pain for 3 hours after receiving the drug, to rate how well it works. They will stay at the clinic up to 6 hours after the surgery. If pain is not relieved with ketorolac, patients will receive a one-time dose of tramadol, a pain medication for moderate to severe pain. After the study procedures are completed, patients will receive pain medication for pain after surgery.
Patients will be monitored closely, because all drugs have side effects. Ketorolac is a nonsteroidal anti-inflammatory drug, one that may cause gastrointestinal upset. Fentanyl is a powerful narcotic drug that is safe at the dosage used in this study, but stomach upset, dizziness, and breathing trouble may occur. Also, risks from the biopsy include discomfort from injecting the numbing medicine, infection, and bleeding. There may be discomfort from the sedative injected into the vein, and there may be bruising.
Benefits from participating are having wisdom teeth removed at no cost as well as close monitoring before and after surgery. There are no plans to give patients the results of genetic tests or questionnaires. Years of research may be needed before such information has the chance to become meaningful.
Conditions
Interventions
- DRUG
-
Valdecoxib
- DRUG
-
COX Inhibitor
Sponsors & Collaborators
-
National Institute of Nursing Research (NINR)
lead NIH
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 7 Years
- Max Age
- 35 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2005-06-20
- Completion
- 2006-10-04
Countries
- United States
Study Locations
More Related Trials
-
CYP4A11 and CYP4F2 Gene Variants as Makers of Cardiovascular Adverse Events of Non-steroidal Anti-inflammatory Drugs
NCT02779530 ·Status: COMPLETED ·Phase: PHASE4
-
Perioperative Inflammation and Cyclooxygenase 2 (COX-2)
NCT00122096 ·Status: COMPLETED ·Phase: PHASE4
-
RN624 In Adult Patients With Chronic Low Back Pain
NCT00584870 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Study PK Study With OXP005 and Naprosyn
NCT02351024 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetics and Safety Study of Naproxcinod in Subjects With Impaired Renal Function
NCT00674856 ·Status: COMPLETED ·Phase: PHASE1
-
Effectiveness of Theramine on Chronic Back Pain
NCT01468025 ·Status: COMPLETED ·Phase: PHASE3
-
A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain
NCT00662558 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Naproxen on Physical Performance
NCT00410995 ·Status: TERMINATED ·Phase: PHASE4
-
Pharmacokinetics Study Comparing Topical Diclofenac/Menthol Gels With Voltaren Gel and Oral Diclofenac Sodium
NCT02201238 ·Status: COMPLETED ·Phase: PHASE1
-
NSAIDs in Sciatica NSAIDS IN SCIATICA
NCT03347929 ·Status: COMPLETED ·Phase: PHASE4
-
Impact of Genetic Polymorphism on Drug-Drug Interactions Involving CYP2D6
NCT03054220 ·Status: COMPLETED ·Phase: NA
-
Study Evaluating the Bioavailability of Naproxen 375 mg in Two Formulations
NCT00692055 ·Status: COMPLETED ·Phase: PHASE1
-
Anti-inflammatory Agents and Cholesterol Metabolism
NCT01279395 ·Status: TERMINATED
-
To Evaluate Whether Naproxen and Darexaban (YM150) Interact in Their Effects
NCT01409603 ·Status: COMPLETED ·Phase: PHASE1
-
NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)
NCT06861920 ·Status: RECRUITING ·Phase: PHASE4
-
Pharmacogenetic and Pharmacokinetics of Naproxen and Associated Naproxen-esomeprazole
NCT03092193 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects
NCT00621881 ·Status: COMPLETED ·Phase: PHASE1
-
PF-06372865 In Subjects With Chronic Low Back Pain
NCT02262754 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Study on Multiple Oral Dosing of CG100649
NCT01154790 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Parecoxib on Patients With CRPS
NCT01523379 ·Status: NO_LONGER_AVAILABLE
-
Naproxen Sodium (2 x 220 mg) Fasted Comparative Bioavailability Study
NCT03167541 ·Status: COMPLETED ·Phase: PHASE1
-
Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)
NCT00007189 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacist-led Pharmacogenomic Clinical Service Within the Program of All-inclusive Care for the Elderly
NCT04971902 ·Status: UNKNOWN
-
A Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects
NCT02108548 ·Status: TERMINATED ·Phase: PHASE1
-
Naproxen Sodium ER Pharmacokinetic Study
NCT00818415 ·Status: COMPLETED ·Phase: PHASE1